| Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in … ML Berger, H Sox, RJ Willke, DL Brixner, HG Eichler, W Goettsch, ... Pharmacoepidemiology and Drug Safety 26 (9), 1033-1039, 2017 | 553 | 2017 |
| Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1. 0 SV Wang, S Schneeweiss, ML Berger, J Brown, F Vries, I Douglas, ... Pharmacoepidemiology and drug safety 26 (9), 1018-1032, 2017 | 213 | 2017 |
| Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. SV Wang, P Verpillat, JA Rassen, A Patrick, EM Garry, DB Bartels Clinical Pharmacology & Therapeutics 99 (3), 325-332, 2016 | 178 | 2016 |
| Estimation using all available covariate information versus a fixed look‐back window for dichotomous covariates SM Brunelli, JJ Gagne, KF Huybrechts, SV Wang, AR Patrick, KJ Rothman, ... Pharmacoepidemiology and drug safety 22 (5), 542-550, 2013 | 87 | 2013 |
| Future-cases as present controls to adjust for exposure-trend bias in case-only studies S Wang, C Linkletter, M Maclure, D Dore, V Mor, S Buka, GA Wellenius Epidemiology (Cambridge, Mass.) 22 (4), 568, 2011 | 85 | 2011 |
| Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses SV Wang, Y Jin, B Fireman, S Gruber, M He, R Wyss, HJ Shin, Y Ma, ... American journal of epidemiology, 2018 | 75 | 2018 |
| A Within‐Group Design of Nontreatment Seeking 5‐HTTLPR Genotyped Alcohol‐Dependent Subjects Receiving Ondansetron and Sertraline GA Kenna, WH Zywiak, JE McGeary, L Leggio, C McGeary, S Wang, ... Alcoholism: Clinical and Experimental Research 33 (2), 315-323, 2009 | 69 | 2009 |
| Persistent user bias in case-crossover studies in pharmacoepidemiology J Hallas, A Pottegård, S Wang, S Schneeweiss, JJ Gagne American journal of epidemiology, 1-9, 2016 | 44 | 2016 |
| Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study SV Wang, JM Franklin, RJ Glynn, S Schneeweiss, W Eddings, JJ Gagne bmj 353, i2607, 2016 | 44 | 2016 |
| Age, Antipsychotics, and the Risk of Ischemic Stroke in the Veterans Health Administration S Wang, C Linkletter, D Dore, V Mor, S Buka, M Maclure Stroke 43 (1), 28-31, 2012 | 42 | 2012 |
| Switching generic antiepileptic drug manufacturer not linked to seizures A case-crossover study AS Kesselheim, K Bykov, JJ Gagne, SV Wang, NK Choudhry Neurology 87 (17), 1796-1801, 2016 | 40 | 2016 |
| Estimating pediatric inpatient medication use in the United States T Lasky, FR Ernst, J Greenspan, S Wang, L Gonzalez Pharmacoepidemiology and drug safety 20 (1), 76-82, 2011 | 40 | 2011 |
| Sentinel Modular Program for Propensity Score–Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia M Zhou, SV Wang, CE Leonard, JJ Gagne, C Fuller, C Hampp, ... Epidemiology 28 (6), 838-846, 2017 | 39 | 2017 |
| Use of electronic healthcare records to identify complex patients with atrial fibrillation for targeted intervention SV Wang, JR Rogers, Y Jin, DW Bates, MA Fischer Journal of the American Medical Informatics Association 24 (2), 339-344, 2017 | 38 | 2017 |
| Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations J Hallas, SV Wang, JJ Gagne, S Schneeweiss, N Pratt, A Pottegård European journal of epidemiology, 1-11, 2018 | 37 | 2018 |
| Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association JJ Gagne, X Han, S Hennessy, CE Leonard, EA Chrischilles, ... Clinical Pharmacology & Therapeutics 100 (5), 558-564, 2016 | 37 | 2016 |
| Performance of disease risk score matching in nested case-control studies: a simulation study RJ Desai, RJ Glynn, S Wang, JJ Gagne American journal of epidemiology 183 (10), 949-957, 2016 | 37 | 2016 |
| Case-crossover Studies of Therapeutics: Design Approaches to Addressing Time-varying Prognosis in Elderly Populations SV Wang, JJ Gagne, RJ Glynn, S Schneeweiss Epidemiology 24 (3), 375-378, 2013 | 35 | 2013 |
| Potential for bias in case-crossover studies with shared exposures analyzed using SAS SV Wang, BA Coull, J Schwartz, MA Mittleman, GA Wellenius American journal of epidemiology 174 (1), 118-124, 2011 | 31 | 2011 |
| Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System EA Chrischilles, JJ Gagne, B Fireman, J Nelson, S Toh, A Shoaibi, ... Pharmacoepidemiology and drug safety, 2018 | 27 | 2018 |
